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Abstract
Background: TRPC6, encoding a member of the transient receptor potential (TRP) superfamily of ion channels, is a calcium-
permeable cation channel, which mediates capacitive calcium entry into the cell. Until today, seven different mutations in
TRPC6 have been identified as a cause of autosomal-dominant focal segmental glomerulosclerosis (FSGS) in adults.
Methodology/Principal Findings: Here we report a novel TRPC6 mutation that leads to early onset FSGS. We identified one
family in whom disease segregated with a novel TRPC6 mutation (M132T), that also affected pediatric individuals as early as
nine years of age. Twenty-one pedigrees compatible with an autosomal-dominant mode of inheritance and biopsy-proven
FSGS were selected from a worldwide cohort of 550 families with steroid resistant nephrotic syndrome (SRNS). Whole cell
current recordings of the mutant TRPC6 channel, compared to the wild-type channel, showed a 3 to 5-fold increase in the
average out- and inward TRPC6 current amplitude. The mean inward calcium current of M132T was 10-fold larger than that
of wild-type TRPC6. Interestingly, M132T mutants also lacked time-dependent inactivation. Generation of a novel double
mutant M132T/N143S did not further augment TRPC6 channel activity.
Conclusions: In summary, our data shows that TRPC6 mediated FSGS can also be found in children. The large increase in
channel currents and impaired channel inactivation caused by the M132T mutant leads to an aggressive phenotype that
underlines the importance of calcium dose channeled through TRPC6.
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Introduction
Focal segmental glomerulosclerosis (FSGS) is the most common
cause of steroid-resistant nephrotic syndrome in both children and
adults [1]. The prognosis of untreated patients with FSGS is poor
as 50–70% of patients will develop end-stage renal failure (ESRF)
[2].
Mutations in podocin (NPHS2) and PLCE1 cause autosomal-
recessive FSGS, whereas autosomal-dominant FSGS is caused by
mutations in WT1, CD2AP, ACTN4 and TRPC6 [3,4,5,6,7,8,9,10].
Autosomal-recessive forms exhibit childhood-onset, whereas
autosomal-dominant forms cause adult-onset nephrotic syndrome
(NS). Monogenic disease genes of NS code for proteins that are
essential for nephron development and an intact podocyte slit
diaphragm [11].
Heterozygous mutations of TRPC6 were recently identified to
cause late-onset autosomal-dominant FSGS [9,10,12]. The
TRPC6 gene is located on the long arm of chromosome 11
(11q22.1) and codes for the short transient receptor potential
canonical 6 (TRPC6). TRPC6 belongs to the family of transient
receptor potential (TRP) channel proteins, a diverse group of
voltage-independent cation-permeable channels that are expressed
in many tissues including lung, kidney, brain, muscle containing
tissues and blood cells where they are involved in many different
signaling cascades of cell growth and mechanosensation [9,13].
The TRPC subfamilies (TRPC1-TRPC7) are important for the
increase of the intracellular Ca
2+ concentration in response to
activation of G-coupled protein receptors and receptor tyrosine
kinases [14]. TRPC6 is a receptor-operated channel and is directly
activated by diacylglycerol (DAG) responding to phospholipase C
(PLC)-mediated signals [15]. In the kidney, TRPC6 is expressed in
both renal tubules and glomeruli, with predominance in
podocytes. TRPC6 is an essential component of the podocyte slit
diaphragm, where it is integrated into a signaling complex that
interacts with nephrin and podocin [10]. A recent study showed
that induction of TRPC6 expression in cultured podocytes causes
loss of actin stress fibers and proteinuria in mice, thereby
suggesting that TRPC6, in podocytes, is functionally connected
to the actin cytoskeleton [16]. The exact pathophysiology through
which dysregulated Ca
2+ influx in patients with TRPC6 mutations
leads to FSGS remains unclear. So far, seven different mutations
in TRPC6 were identified in seven different families from different
ethnic backgrounds [9,10,12]. All patients manifested with disease
between ages 18 and 57. Four of these seven mutations (R895C,
E897K, P112Q and Q889K) allow significantly higher Ca
2+
currents compared to wild-type TRPC6 Ca
2+ current. Moreover,
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higher cellular calcium during acquired proteinuria syndromes.
These findings suggest high abundance of wild-type TRPC6
channels in podocytes contribute to a similar pathophysiology as
the presence of mutated, overly active channels. The fact that both
hyperactive mutated as well as high expression of wt TRPC6 can
cause proteinuria syndromes with different onset time, suggests
that the level of calcium available in the foot process is a
determining factor for disease activity. Comparison of average
inward and outward channel currents and inactivation time of all
published mutations shows that all mutations lead to increased
TRPC6 channel activity by one of the above mechanisms, M132T
calcium peak influx is the largest calcium peak influx described so
far (Table 1). The results from this paper supports the hypothesis
of calcium dose-response dependency showing that a novel human
mutation with largest calcium peak influx and strong delay of
channel activity can lead to early FSGS.
We performed mutation analysis of TRPC6 in 21 familial cases
with FSGS that were compatible with autosomal-dominant
inheritance and identified a novel TRPC6 mutation as the cause
of FSGS. One patient manifested disease already at the age of 9.
To study the effect of M132T on calcium channel function, we
expressed wild-type, M132T and a newly generated double
mutant M132T/N143S in HM1 cells (human embryonic kidney
cells stably transfected with the M1 muscarinic receptor). The
M132T mutant increased TRPC6 in- and outward Ca
2+ currents
significantly, compared to wild-type TRPC6 currents. In contrast
to the wild-type TRPC6 current, the mutant M132T did not show
inactivation after reaching a peak level upon activation, and only a
minor decline of inward current was observed, representing a new
variant of TRPC6 dysfunction.
Results
Patient Characteristics
We ascertained 52 individuals with FSGS from 21 families in
whom disease segregation was compatible with an autosomal
dominant pattern. At least one affected individual in each family
had biopsy proven FSGS. We identified 14 families with two
affected members, five families with three affected members, one
family with four affected members and one family with five
affected members (Table S1). No patients had mutations in
NPHS2 and WT-1. Age at onset of disease was documented in 38
patients. The median age at onset of disease was 17.5 years (range
2–70 years). Patient recruitment for this study was worldwide with
a predominance of (Central) European individuals. Clinical
characteristics are listed in Table S1.
TRPC6 Mutation Analysis
Mutation analysis of TRPC6 by direct exon sequencing of all 13
exons was performed in at least one affected individual with biopsy
proven FSGS from all 21 selected families. In family F505, a two-
affected family from Turkish descent, we detected a novel TRPC6
mutation which segregated with disease (Figure 1A). Family
member III-2 manifested disease at 30 years of age and has biopsy
proven FSGS. Her son, IV-1, manifested disease at the age of 9
and also has biopsy proven FSGS. Both affecteds had steroid-
resistant nephrotic syndrome (SRNS) and developed end-stage
renal failure 0.5 (III-2) and 9.5 (IV-1) years after onset,
respectively.
The mutation changes a T to a C in exon 5 (c.495T.C), which
substitutes a Methionine to a Tryptophan (M132T) (Figure 1B).
This amino acid is highly conserved through evolution even in
Drosophila Melanogaster (Figure 1C) and is located in the second
intracellular ankyrin repeat of the TRPC6 protein. The mutation
was absent from .140 healthy control individuals.
The following innocuous sequence variants that represent
known single nucleotide polymorphisms (SNPs) were found:
P15S; SNP rs3802829 was found in seven patients A404V; SNP
rs36111323 was found in seven additional patients. All of the other
sequence variants that were found in this cohort (p.N561N,
p.Y705Y, p.F843F and p.Q904Q) did not result in an amino acid
change.
Electrophysiological Analysis of Mutant and Wild-Type
TRPC6
In order to access the functional significance of the M132T
mutation, TRPC6 current was recorded after 36–48 hrs transfec-
tion by a voltage ramp protocol ranging from 2120 to +100 mV.
Figure 2A shows wt TRPC6 current elicited by 100 mM
Table 1. Genotype-phenotype correlation of all published mutations.
Mutation
Averaged inward current
amplitude of the mutant
channel
Average increase in
inward current of
mutant channel vs
WT channel
Increase in Ca2+
currents or influx
of mutant channel
vs wt channel
Delayed channel
inactivation Activation by
Age at onset
of disease
(in years) Reference
M132T 2701 pA/pF (2120 mV) 6.7 10 Yes** CCh 9–30 current study
P112Q 29 nA (100 mM UTP) 3 1.7 nd UTP 18–56 9
P112Q nd nd 1.7 nd Ang-2 18–56 9
R895C 2230 (2100 mV) 7.7 nd No CCh 18–46 10
E897K 2150 (2100 mV) 5 nd No CCh 24–35 10
N143S 2300 pA/pF (2120 mV) 2.1 - No** - 27–39 current study
S270T 243.1 pA/pF 20.6* - Yes** CCh 17–52 10, current study
K874X 2112.3 pA/pF 0.08 - Yes** CCh 27–57 10, current study
Q889K nd nd 7,5 nd OAG 35–41 12
CCh=Carbachol; UTP=uridine 59-triphosphate; Ang-2=Angiotensin II; nd=not done.
*S270 current was smaller than wt TRPC6. The inward currents ratio: N143s/WT=2.1; K874X/WT=0.08.
**M132T did not inactivate within 100 s. On average, WT and N143S inactivated by 60% within 10–20 s; whereas S270T and K874X inactivated by 10–15% within
79–90 s.
doi:10.1371/journal.pone.0007771.t001
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amplitude (Figure 2B) indicated that TRPC6 was rapidly
activated and reached a peak level after the cell was stimulated
by 100 mM CCh. TRPC6 current then declined to about 50% of
the peak current level and maintained at a sustained current level.
No current was activated before application of CCH (Figure 2A).
Interestingly, the mutant M132T exhibited significantly increased
current amplitude (Figure 2C). The average outward and inward
current amplitudes of M132T were almost 3- and 5-fold bigger
than that of wt TRPC6 (Figure 3). The second remarkable
difference between M132T and the wt TRPC6 was that M132T
did not show inactivation and only minor time-dependent decline
of inward current was observed (Figure 2D). The position of
M132T is close to the previously reported mutation N143S and
occurs within the same ankyrin domain [10]. To test if M132T has
reached a limit for gain-in function, we created a TRPC6 double
mutant M132T/N143S in order to study positive additive effects
on channel kinetics. We first tested the properties of the known
FSGS mutant TRPC6-N143S alone. As shown in Figure 2E–F,
N143S displayed similar rapid activation and inactivation as
observed in wt TRPC6. However, the peak inward current
amplitude of N143S was bigger than that of wt TRPC6. The peak
outward current amplitude as well as the sustained currents (after
inactivation) of N143S were not significantly different from wt
TRPC6. The properties of the double mutant M132T/N143S
resulted in a similar current characteristic than the one observed
for M132T (Figure 2G–H). M132T/N143S current rapidly
reached a peak upon CCh application, and very little time-
dependent inactivation was observed (Figure 2H). The averaged
inward and outward current amplitudes, and the ratio of inward/
outward current of wt TRPC6, N143S, M132T, and M132T/
N143S are shown in Figure 3 (n=10 for each group).
As TRPC6 is a non-selective cation channel, we further
compared inward Ca
2+ current amplitude of the mutants and
the wt TRPC6. These experiments were conducted under the
conditions that Ca
2+ was the only permeate cation in the external
solution. As shown in Figure 4A, the inward Ca
2+ currents of
M132T and M132T/N143S were significantly larger than those
of wt TRPC6 and N143S. The smaller Ca
2+ current amplitudes of
N143S and wt TRPC6 are consistent with their transient
activation feature as shown in Figure 2B and 2F. The mean
inward calcium current of M132T and M132T/N143S was ,10
fold larger than that of wt TRPC6 and N143S (Figure 4B).
Discussion
This study represents one of the largest cohorts of FSGS families
compatible with autosomal- dominant inheritance that was
examined for TRPC6 mutations. In one of 21 FSGS families that
were compatible with autosomal-dominant segregation and
screened for mutations, we identified a novel heterozygous
disease-causing mutation in TRPC6, leading to early-onset FSGS
in one of two affected individuals. The mutated ion channel causes
a very significant increase in inward and outward currents and
does not show channel inactivation. Only seven different TRPC6
mutations in seven families have been identified so far, all leading
to late-onset FSGS [9,10,12], whereas M132T mutation results in
childhood FSGS.
We were able to show by whole cell current recordings, that
M132T inward currents compared to the wild-type, were almost
7-fold increased after stimulation by Carbachol. The average
outward and inward current amplitudes were 3 to 5-fold increased
compared to wild-type, and inward Ca
2+ current amplitude of the
M132T mutant was almost 10-fold larger than wild type. We also
observed that the M132T mutant did not show channel
inactivation, in contrast to the wild-type channel whose current
declined to 50% of the peak current level after reaching a peak
level. Four of the previously reported TRPC6 mutations (P112Q,
R895C, E897K and Q899K) also showed gain of function in
Figure 1. Segregation and Evolutionary conservation of
M132T. (A) Pedigree of FSGS Family F505 with affecteds III-2 and IV-
1 is compatible with autosomal/dominant inheritance. Filled symbols
denote individuals affected with FSGS. Age at onset (years) is shown in
parentheses. (B) TRPC6 mutation in F505. Nucleotide and amino acid
change for M132T are given above sequence traces. The normal control
(NC) sequence is shown below the mutated sequence. Reading frame is
indicated by underlining all codon triplets in the chromatogram. (C)
Evolutionary conservation of TRPC6 The Met
132 is highly conserved
through evolution down to Drosophila Melanogaster.
doi:10.1371/journal.pone.0007771.g001
TRPC6 Mutant in Childhood FSGS
PLoS ONE | www.plosone.org 3 November 2009 | Volume 4 | Issue 11 | e7771Figure 2. Gain of function of TRPC6 mutants M132T and M132T/N143S. A, C, E, and G: Representative currents elicited by voltage-ramp
protocol ranging from 2120 to +100 mV in the presence of 100 mM Carbachol (CCh) in wt TRPC6 (A), M132T (C), N143S (E), and M132T/143S (G). No
activation was observed before 100 mM CCh stimulation. B, D, F, and H: Time-dependent changes of inward current measured at 2120 mV and
outward current measured at +100 mV of wt TRPC6 (B), M132T (D), N143S (F), and M132T/143S (H). TRPC6 and the mutants were only activated after
application of 100 mM CCH. In both panel D and H, N-methyl D-glucamine (NMDG) was applied to confirm that there was no leak current. For panel B
and F, there was no significant difference of the sustained current amplitude between wt TRPC6 and N143S.
doi:10.1371/journal.pone.0007771.g002
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2+ influx and
increased current amplitude upon activation [9,10,12]. The
S270T and K874Stop mutants displayed increased time to
channel inactivation and thus led to a gain of function in the
TRPC6 cation channel. (10) In this study, we directly compared
the different times to inactivation and average inward and outward
channel currents of all published mutations, see Table 1.
Interestingly, M132T mutant did not show any inactivation within
100 s, the S270T and K874X mutants showed slight inactivation
of 10–15% within 79–90 s. In summary, these results show that all
of the TRPC6 mutations identified thus far lead to increased
activity of TRPC6 ion channels, either by increasing current
amplitude or by delaying channel inactivation.
Both the impaired inactivation of M132T, as well as the 10-fold
increase in mean inward calcium current of M132T, provide an
explanation for the early onset of SRNS in F505 IV-1. Our data
supports the concept that mutations leading to a more pronounced
increase in calcium influx, in this case by both direct increase in
calcium influx and an impaired channel inactivation, also cause a
more severe or possibly an earlier disease onset. As previous
reported patients with disease-causing TRPC6 mutations all
manifested between the ages of 18 and 57, see Table 1, the
consideration of mutated TRPC6 was rejected for children with
renal disease. Since this is the first time that a TRPC6 mutation is
shown to cause early-onset FSGS, it is required to consider
mutated TRPC6 as a possible cause for renal failure in children.
The N143S mutation, which was previously reported by Reiser
et al, is located very close to M132T, within the same ankyrin
repeat.(10) As of their close location, we expected channel kinetics
of both mutants to be similar. Originally, N143S currents were
described as not noticeably different from the wild-type TRPC6
peak channel activity.(10) In this study, the outward peak current
of the N143S mutant again was not significantly different from the
WT current, but caused a significant increase in the inward peak
current amplitude (Figure 3B).
As M132T has such a strong Calcium current, and as the
N143S and M132T mutations are located within the same ankyrin
domain, we intended to investigate if two mutations in the N
terminus would have a possible additive effect with respect to
channel function. We therefore tested the effect of a double
M132T/N143S mutant, hypothesizing an exponential increase of
Calcium influx and time to channel inactivation. Current
amplitudes of the double mutant M132T/N143S were however
similar to the M132T mutant, but did not show a larger increase
in current amplitude than the M132T mutant alone (Figure 3).
Two mutations in the same domain cannot cause an exponential
additive effect or change in channel kinetics and increase Calcium
influx any further.
M132T leads to a comparably higher TRPC6 Calcium current
than all other known mutations, even so one needs to carefully
interpret this data considering that different TRPC6 channel
stimulants have been used between the individual published
studies. The high Calcium current of M132T in podocytes might
serve as an explanation for the cause of an early onset FSGS
disease in these patients.
The concept of calcium dose effect determining the time of
disease onset is also supported by animal experiments where it was
shown that transient overexpression of wild-type TRPC6 in
murine glomeruli leads to rapid onset proteinuria and that
elevated expression levels of TRPC6 are detected in different
acquired human glomerular diseases [16]. While the idea of the
amount of channeled calcium into podocytes as time-determining
factor is certainly attractive, other contributing elements to
TRPC6 disease onset need to be considered. For example, it
Figure 3. Averaged current amplitude of wt TRPC6 and the
mutants. A: Outward current amplitude measured at +100 mV
(mean6SEM, n=10). The outward current amplitude of M132T and
M132T/N143S was significantly bigger than that of wt TRPC6. B: Inward
current amplitude measured at 2120 mV (mean6SEM, n=10). The
inward current amplitude of N143S, M132T, and M132T/N143S was
statistically larger than that of wt TRPC6. C: The ratio of inward/outward
current amplitude. Note the current amplitude of wt TRPC6 and N143S
was measured at the peak inward and outward current amplitude (as
shown in Figure 2). (*: p,0.05, **: p,0.01, in comparison with wt TRPC6).
doi:10.1371/journal.pone.0007771.g003
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expressed at the cell surface and it was speculated that the altered
subcellular trafficking could explain the enhanced channel activity
[9,17].
Evidence for TRPC6 playing an essential role in slit diaphragm
signaling pathways has become robust over time. Interaction with
podocin and nephrin in the slit diaphragm was shown [10], and
binding to -actinin-1, -actinin-4 and calcineurin has also been
reported [10,18]. It is possible that TRPC6-mediated calcium
influx regulates the actin cytoskeleton through pathways involving
calcineurin. It was recently shown that the calcineurin-synapto-
podin pathway could be a potential mediator of proteinuria. With
calcineurin being a calcium-sensitive serin-threonine phosphatase,
TRPC6 mediated calcium changes are an excellent candidate to
directly affect cytoskeletal integrity of podocytes and thus
glomerular barrier function [19]. The increased calcium influx
through mutated TRPC6 into the cells might disrupt cytoskeletal
response to physiological changes, thereby causing proteinuria
[20]. Another pathophysiological explanation for proteinuria in
patients with TRPC6 mutations would be the dysfunction of
mechanosensation in the slit diaphragm. Multiple TRP channel
family members have been reported to be involved in mechan-
osensation, and altered TRPC6 channel function could influence
podocyte sense for flow, stretch or pressure, thereby in turn
affecting the reorganization of the podocyte actin cytoskeleton in
response to physiological changes [20,21]. The recent finding that
podocin through cholesterol recruitment provides mechanosensi-
tive properties to ion channels such as TRPC6, adds to the notion
that the podocyte slit diaphragm relates information into podocyte
foot processes [10,22,23]. Impaired cytoskeletal reorganization
could be envisioned as a result of defective mechanosensation (e.g.
through hyperactive TRPC6), which in turn leads to podocyte
damage, podocyte loss and, ultimately, FSGS. In case of M132T
mutation, this process would be enhanced.
Whatever the precise possibilities are that lead to increased
compartmentalized calcium in podocyte foot processes, M132T is
certainly one of them that together with other mechanisms
requires us to consider large increase in TRPC6 channel currents
as causative factors for early-onset FSGS. It is therefore advisable
to screen already children in which FSGS segregates in an
autosomal dominant mode, for mutations in TRPC6.
Materials and Methods
Patient and Data Recruitment
Within a worldwide cohort of 550 families with child-hood or
adult-hood onset of FSGS, we selected 21 families with biopsy
proven FSGS in affected individuals whom inheritance was
consistent with an autosomal-dominant pattern. In affected
individuals, we performed mutation analysis by direct exon
sequencing for all 13 exons of TRPC6. All patients were also
examined for mutations in NPHS2 and exons 8 and 9 of WT1
(Wilms’ tumor-1) as these are a frequent cause of FSGS [24].
Human subjects research was approved by the University of
Michigan Institutional Review Board and the Ethics Committee of
the University of Freiburg, Germany. At least one affected
individual per family had biopsy proven FSGS and nephrotic
syndrome, diagnosed by nephrologists in specialized centers based
on published criteria [25]. We obtained informed consent, detailed
clinical and pedigree information by a standardized questionnaire
completed available on www.renalgenes.org [26].
Mutation Analysis
Genomic DNA was isolated from blood samples using the
PuregeneH DNA purification kit (Gentra, Minneapolis, MN)
following the manufacturer’s guidelines. Mutation analysis by
direct exon sequencing was performed using exon-flanking
primers. TRPC6 exon primers are listed in Table S2. Exon
primers for NPHS2 and WT1 have been published previously [26].
For sequence analysis the software SEQUENCHER
TM (Gene
Codes, Ann Arbor, MI) was used. The published reference
sequence of human TRPC6 (NM_004621) was used as the relevant
wild-type gene sequence. Sequencing of both strands was
performed for the detected mutation. For the novel mutations
their absence was demonstrated in .140 healthy individuals of
matched ethnic origin by restriction-enzyme digest.
Site-Directed Mutagenesis of the TRPC6 Plasmids
We introduced the M132T mutation into a full length human
TRPC6 cDNA clone by site-directed mutagenesis using the
QuikChange Lightning Site Directed Mutagenesis Kit
TM (Strata-
gene) according to the manufacturer’s instructions. Mutagenic
oligonucleotide primers containing the desired mutations were
Figure 4. Increase in Ca
2+ current in mutantsN143S, M132T and M132T/N143S. A: Inward current of wt TRPC6 and the mutants measured
at 2120 mV in the presence of 100 mM CCH. Inward current level was close to 0 pA level in NMDG solution, and increased after the cell was exposed
to 10 mM calcium/NMDG solutions. Note the significant larger calcium current amplitude of M132T and M132T/N143S in comparison with wt TRPC6
and M143S. B: Averaged current amplitude of wt TRPC6, N143S, M132T, and M132T/N143S at 2120 mV (mean6SEM, n=427). (**: p,0.01 in
comparison with wt TRPC6).
doi:10.1371/journal.pone.0007771.g004
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coding for non-tagged human wildtype TRPC6, FLAG-tagged
human wildtype TRPC6, FLAG-tagged human TRPC6 carrying
the N143S mutation [10], and a cDNA coding for the FLAG-
tagged, dominant-negative human TRPC6 pore mutant all
subcloned in the pcDNA3 vector (Invitrogen), served as templates
for site-directed mutagenesis [27]. To confirm the identity of the
N143/N143S and M132/M132T sites, both template and
M132T-mutated plasmids were sequenced in quadruplicate.
Electrophysiological Analysis of Mutant and Wild-Type
TRPC6
HM1 cells (human embryonic kidney cells stably transfected
with the M1 muscarinic receptor) were transiently transfected with
wild-type (WT) TRPC6 or its mutants [28]. Electrophysiological
recordings were conducted between 36–48 h after transfection. All
patch-clamp experiments were performed at room temperature
(20–25uC). Whole-cell currents were recorded using an Axopatch
200B amplifier. Patch electrodes were pulled from borosilicate
glass and fire-polished to a resistance of ,2M V when filled with
internal pipette solutions. Series resistance (Rs) was compensated
up to 90% to reduce series resistance errors to ,5 mV. Cells in
which Rs was .10 MV were discarded [29]. For whole cell
currents recordings, voltage stimuli lasting 250 ms were delivered
at 1- to 5-s intervals, with voltage ramps ranging from 2120 to
+100 mV. The holding potential was 0 mV. A fast perfusion
system was used to exchange extracellular solutions, with complete
solution exchange achieved in ,1 to 3 s [30]. The internal pipette
solution for whole cell current recordings contains (in mM) 145
Cs-methanesulfonate, 10 NaCl, 2 Mg-ATP, 0.2 Na-GTP, 1
EGTA, 0.38 CaCl2 and 10 HEPES buffer (pH 7.2 adjusted with
CsOH). Free calcium concentration in the pipette solution was
100 nM as calculated by MaxChelator. The standard extracellular
Tyrode’s solution for whole cell current recording contains (mM):
145 NaCl, 5 KCl, 2 CaCl2, 1 MgCl2, 10 HEPES and 10 glucose;
pH was adjusted to 7.4 with NaOH, and osmolarity was adjusted
to ,300 mOsm. N-methyl D-glucamine (NMDG) solution was
prepared using (mM) 145 NMDG-Cl, 10 HEPES, and 10 glucose
(pH 7.4). For some experiments, 10 mM Ca
2+ was prepared in
NMDG solution. The concentration of NMDG was reduced
accordingly in order to keep the identical osmolarity.
Statistical Analysis
Pooled data are presented as mean6SEM. Statistical compar-
isons were conducted by using one-way ANALYSIS of variance
(ANOVA) and two-tailed t-test with Bonferroni correction;
P,0.05 was chosen for statistical significance.
Supporting Information
Table S1 Clinical characteristics of 21 families with FSGS
compatible with autosomal dominant segregation-sensitive ne-
phrotic syndrome.
Found at: doi:10.1371/journal.pone.0007771.s001 (0.11 MB
DOC)
Table S2 Primer sequences for all 13 exons of TRPC6.
Found at: doi:10.1371/journal.pone.0007771.s002 (0.03 MB
DOC)
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